Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Bayer Seeks To Buy Monsanto in $66 Billion Deal

XTALKS VITALS NEWS

Best known for the discovery of aspirin, Bayer’s acquisition of Monsanto would make it the world’s largest seed and crop spray supplier.

Tweetables from this article:

Tweet: Monsanto and Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil http://ctt.ec/ODRnv+Monsanto and Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil.

Share this!

September 21, 2016 | by Sarah Hand, M.Sc.

German pharmaceutical company Bayer has announced its intention to acquire the US-based agribusiness company Monsanto in a $66 billion deal. Best known for the discovery of aspirin, Bayer’s acquisition of Monsanto would make it the world’s largest seed and crop spray supplier.

After four months of negotiations, the companies have agreed upon an all-cash deal valuing Monsanto’s shares at $128 apiece. Hugh Grant, CEO of Monsanto will reportedly earn over $135 million if the sale goes through.

“Today’s announcement is a testament to everything we’ve achieved and the value that we have created for our stakeholders at Monsanto,” said Grant. “We believe that this combination with Bayer represents the most compelling value for our shareowners, with the most certainty through the all-cash consideration.”

Despite mutual agreement between the two companies, the merger will now face the scrutiny of US regulators. Following last year’s merger between Dow Chemical and DuPont, and this year’s deal between ChemChina and Syngenta, the number of global companies in agribusiness is quickly shrinking.



Industry experts are pointing to bumper harvests and declining crop prices as a main driver of consolidation in the agricultural industry. According to farmer’s groups, this reduction in the number of different companies investing in new agricultural technologies could drive up the cost of proprietary seeds and chemical sprays.

If they’re successful, the Bayer-Monsanto merger will be the largest cash only deal on record, as well as the biggest acquisition of an American company by an overseas business. To complete the deal, Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil.

“We are entering a new era in agriculture – one with significant challenges that demand new, sustainable solutions and technologies to enable growers to produce more with less,” said Grant. “This combination with Bayer will deliver just that – an innovation engine that pairs Bayer’s crop protection portfolio with our world-class seeds and traits and digital agriculture tools to help growers overcome the obstacles of tomorrow. Together Monsanto and Bayer will build on our proud tradition and respective track records of innovation in the agriculture industry, delivering a more comprehensive and broader set of solutions to growers.”


Keywords: Merger, Agribusiness, Aspirin


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.